Regulators of fibrinolysis in chronic viral pathology of the liver


Cite item

Full Text

Abstract

Aim. To investigate a clinicopathogenetic role of fibrinolysis regulators in chronic viral hepatitis (CVH) and viral cyrrhosis of the liver (CL).
Material and methods. Seventy patients entered the study: 10 patients with CVH B, 33 - with CVH C, 6 - with CVH D, 21 - with viral CL (HCV-associated in 14 cases and HBV-associated in 7 cases. A concentration and activity of tissue plasminogen activator (TPA), the level of plasminogen-1 activator inhibitor (PAI-1) in blood plasma were estimated with enzyme immunoassay (Technoclone GmbH, Austria). PAI-1/TPA was estimated.
Results. Increased TPA, PAI-1 concentrations and TPA activity in plasma with maximal values in CL were found. Most severe imbalance in the system of fibrinolysis regulators occurs in poor-prognosis cirrhosis and decompensated portal hypertension. High TPA concentration and activity in CL have a positive correlation with the Child-Pugh index, while low PAI-1/TPA correlates negatively with this index.
Conclusion. TPA and PAI-1 correlations with hemorrhagic manifestations and prognosis of the disease suggest an essential clinical role of fibrinolysis regulators in chronic viral pathology of the liver.

References

  1. Amitrano L., Guardascione M. A., Brancaccio V., Balzano A. Coagulation disorders in liver disease. Semin. Liver Dis. 2002; 22 (1): 83-96.
  2. Caldwell S. H., Hoffman M., Lisman T. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44 (4): 1039-1046.
  3. Colucci M., Binetti B. M., Branca M. G. et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38 (1): 230-237.
  4. Kahl B. S., Schwartz B. S., Mosher D. F. Profound imbalance of profibrinolytic and antifibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type I) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation. Blood Coagul. Fibrinol. 2003; 14 (8): 741-744.
  5. Van Thiel D. H., George M., Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb. Haemost. 2001; 85 (4): 667-670.
  6. Hu K. Q., Yu A. S., Tiyyagura L. et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am. J. Gastroenterol. 2001; 96 (5): 1581-1586.
  7. Knittel T., Fellmer P., Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology 1996; 111: 745-754.
  8. Noguchi T., Matsuyama S., Akao M. et al. Induction of hepatic tissue-type plasminogen activator and type 1 plasminogen activator-inhibitor gene expression and appearance of their translation products in the bile following acute liver injury in rats. Thromb. Res. 2001; 104 (4): 283-291.
  9. Currier A. R., Sabla G., Locaputo S. et al. Plasminogen directs the pleiotropic effects of uPA in liver injury and repair. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 284 (3): 508-515.
  10. Nomura K., Miyagawa S., Ayukawa K. et al. Inhibition of urokinase-type plasminogen activator delays expression of c-jun, activated transforming growth factorb1, and matrix metalloproteinase 2 during post-hepatectomy liver regeneration in mice. J. Hepatol. 2002; 36 (5): 637-644.
  11. Shimizu M., Hara A., Okuno M. et al. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology 2001; 33: 569-576.
  12. Benyon R., Arthur M. J. P. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 2001; 21 (3): 373-384.
  13. Hayashi T., Kobayashi Y., Yamaguchi K. et al. The clinical significance of plasma tissue plasminogen activator (t-PA) levels in severe acute or fulminant hepatitis. Nippon Shokakibyo Gakkai Zasshi 1998; 95 (3): 214-220.
  14. Aleman-Valls M. R., Gonzalez-Reimers E., Santolaria-Fernandez F. et al. Lack of relationship between plasma thrombomodulin and portal hypertension in alcoholic liver disease. Alcohol 2000; 20 (2): 205-206.
  15. Inoue K., Sugawara Y., Kubota K. et al. Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion. J. Hepatol. 2000; 33 (3): 407-414.
  16. Raya-Sanchez J. M., Gonzalez-Reimers E., Rodriguez-Martin J. M. et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15 (1): 19-23.
  17. Wu X. R., Lu M. H., Wang Q. et al. The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis. Zhonghua Gan Zang Bing Za Zhi 2004; 12 (7): 400-402.
  18. Hayashi T., Kamogawa A., Yamaguchi R. S. et al. Plasma from patients with cirrhosis increases tissue plasminogen activator release from vascular endothelial cells in vitro. Liver 1998; 18 (3): 186-190.
  19. Agarwal S., Joyner K. A. Jr., Swaim M. W. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am. J. Gastroenterol. 2001; 96 (11): 3218-3224.
  20. Gutierrez A., Sanchez-Paya J., Marco P., Perez-Mateo M. Prognostic value of fibrinolytic tests for hospital outcome in patients with acute upper gastrointestinal hemorrhage. J. Clin. Gastroenterol. 2001; 32 (4): 315-318.
  21. Piscaglia F., Siringo S., Hermida R. C. et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis an esophageal varices. Hepatology 2000; 31 (2): 349-357.
  22. Yun J. W., Kim B. I., Chun H. B. et al. Fibrinolytic activities and their relations to esophageal variceal bleeding in patients with liver cirrhosis. Korean J. Gastroenterol. 2004; 43 (6): 349-354.
  23. de Petro G., Tavian D., Copeta A. et al. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA mssenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998; 58 (10): 2234-2239.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies